Inmediatamente después de su anuncio de compra Chemtura AgroSolutions en abril y Agriphar En agosto, Platform Specialty Products Corp., con sede en EE. UU., acordó comprar Arysta LifeScience por $3,51 mil millones. Arysta tiene 3.600 registros de productos en más de 100 países e ingresos de $1.5 mil millones en 2013.
Just as the company said with its previous acquisitions, Platform says Arysta is in line with the company’s “asset-lite, high-touch” business model, which means that Platform likes being a post-patent company that doesn’t originate active ingredients. Instead it plans to capitalize on highly differentiated, specialized and localized products and formulations driven by Arysta’s 1,300 sales and marketing professionals.
Platform’s businesses generated $746 million in 2013, so the Arysta deal will more than double company revenues. Company founder and Chairman Martin Franklin hints that it is still looking for other deals in crop protection.
“This is a watershed event for Platform. Over the past twelve months we have demonstrated significant progress and exercised tremendous discipline as we executed against our build-up strategy,” Franklins said in a presione soltar. “Through the acquisitions of Arysta, CAS, and Agriphar we have established a leading position within an attractive asset-lite, high-touch specialty chemicals vertical. As we work to accelerate the organic growth within these businesses, we remain opportunistic on the acquisition front and will look to strategically expand our portfolio across other attractive, niche verticals. The management teams we have assembled through our acquisitions provide us with some of the best talent in the industry, and I am confident that by working together, each of our businesses will thrive and create increasing value for our shareholders.”
Read the full announcement on Platform’s website.